摘要
The breakthrough invention of induced pluripotent stem cells(iPSCs)ignited huge excitement with the promise of unlimited autologous cell sources for future regenerative medicine.1,2 However,before this expectation turns into reality the safety and efficacy of these autologous cell products have to be meticulously evaluated and validated.Towards this end much research effort has been concentrated on three clinically relevant aspects:tumorigenesis,immunogenesis,and efficacy.
